Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 144,377 shares, a drop of 33.3% from the November 30th total of 216,616 shares. Based on an average daily trading volume, of 5,310 shares, the days-to-cover ratio is presently 27.2 days. Based on an average daily trading volume, of 5,310 shares, the days-to-cover ratio is presently 27.2 days.

Innovent Biologics Stock Performance

Shares of IVBXF traded up $0.02 during mid-day trading on Tuesday, hitting $10.13. The stock had a trading volume of 16,565 shares, compared to its average volume of 32,763. The business has a fifty day moving average price of $11.21 and a 200-day moving average price of $11.58. Innovent Biologics has a 52 week low of $3.91 and a 52 week high of $15.12.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).